Will VIVUS Prove Doubters Wrong?

In anticipation of its presentation at the J.P. Morgan Global Healthcare Conference, obesity drugmaker VIVUS (NASDAQ: VVUS  ) released its presentation in an SEC filing. Investors were particularly impressed with the improved prescription data for Qsymia, and shares jumped around 8% today on this news. In the following video, health care analyst Max Macaluso discusses this news, reasons for why Qsymia prescriptions are gaining momentum, and what this means for Arena Pharmaceuticals (NASDAQ: ARNA  )  -- VIVUS' main competitor in the obesity drug market.

Shares of VIVUS have been under pressure since Qsymia's initial sales numbers were released in November, but the stock is still up 45% in the last 12 months. While the jury's out on this biotech's long-term success, some investors were able to make great returns by recognizing the game-changing potential of its recently approved obesity drug. That is the same mind-set that Motley Fool co-founder David Gardner's often uses to pick stocks that frequently trounce the market. He's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.


Read/Post Comments (3) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 09, 2013, at 6:29 AM, RSRdriver wrote:

    Look, If you are going to continue to write these "articles" or continue to bark at the people passing by on the "street" to come into your tent! At least use this forum for something besides a way to try and prove your worth to the investment community.

    Why don't one of you strap on a set and tell the world the truth about ARNA and Belviq. If we want to read rehashes of old news and others articles, we can read Flagboys Areniac buttkissing "articles on Seeking Alpo.

  • Report this Comment On January 09, 2013, at 9:24 AM, feelinIrie wrote:

    RS Driver,

    Seems the article has gotten under your skin and the truth hurts.

    Arena and Belviq is the SAFEST ( No black box labeking for it, cough cough) and they will be going global and are already establishing partnerships outside of the U.S.

    VVUS has recieved EU REJECTION for a reason, so maybe they should start advertising here in the U.S. (OOPS, I forgot, they are not allowed to.

    Bottomline is ARNA is the true winner and as susual...

    ARNA SHORTS ARE TOAST!!!

  • Report this Comment On January 09, 2013, at 9:43 AM, RSRdriver wrote:

    I invite the reader to read the posts made by this Feeline character.

    This is a typical Areniac. Where they managed to find them this dumb is still under debate here. Some think that the message boards at the village and elsewhere. Iam of the op. that they are really the same 6 "writers" who post the pathetic pump articles here and on Seeking Alpo.

    This whole ARNA thing smells of a conspiracy to defraud.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2182693, ~/Articles/ArticleHandler.aspx, 10/23/2014 9:23:46 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement